Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom

被引：0

作者：

Pillay, D ^{[1
]}

Green, H ^{[1
]}

Matthias, R ^{[1
]}

Dunn, D ^{[1
]}

Phillips, A ^{[1
]}

Sabin, C ^{[1
]}

Evans, B ^{[1
]}

Cane, P ^{[1
]}

Burns, S ^{[1
]}

Cameron, S ^{[1
]}

Chrystie, I ^{[1
]}

Churchill, D ^{[1
]}

Clarke, J ^{[1
]}

Easterbrook, P ^{[1
]}

Zuckerman, M ^{[1
]}

Goldberg, D ^{[1
]}

Gompels, M ^{[1
]}

Hale, T ^{[1
]}

Robb, G ^{[1
]}

Leigh-Brown, A ^{[1
]}

Geretti, AM ^{[1
]}

Pillay, D ^{[1
]}

Phillips, A ^{[1
]}

Sabin, C ^{[1
]}

Kellam, P ^{[1
]}

Dunn, D ^{[1
]}

Porter, K ^{[1
]}

Matthias, R ^{[1
]}

Orkin, C ^{[1
]}

Pozniak, A ^{[1
]}

Smit, R ^{[1
]}

Tilston, P ^{[1
]}

Williams, I ^{[1
]}

机构：

[1] UCL, Ctr Virol, Div Infect & Immun, Windeyer Inst, London W1T 4JF, England

来源：

JOURNAL OF INFECTIOUS DISEASES | 2005年 / 192卷 / 06期

基金：

英国医学研究理事会;

关键词：

THERAPY; TRANSMISSION; PREVALENCE; LAMIVUDINE; MUTATION; VIRUS;

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Good estimates of the prevalence of human immunodeficiency virus drug resistance are important for assessing requirements for new drug classes and modeling the spread of resistance. However, little consensus exists on optimal methodologies to generate such data. To compare methodologies, we used the national data set of resistance tests from 14000 patients in the United Kingdom performed between 1998 and 2002. When single-time-point analysis ( method 1) was used, the proportion of tests with any form of resistance was similar to 80%, with little time trend. When a cumulative model of resistance ( method 2) was used and placed in the context of all treated patients, the prevalence of any resistance increased by year, reaching 17% of treated patients in 2002. Method 2 also nearly doubles estimates of numbers of individuals infected with multiclass drug-resistant virus. Our results identify an urgent need for new drugs within existing classes and new classes of antiretroviral therapy.

引用

页码：967 / 973

页数：7

共 26 条

[1]

Blackham J, 2005, AIDS, V19, P487, DOI 10.1097/01.aids.0000162337.58557.3d

[2]

Brown AJL, 2003, J INFECT DIS, V187, P683, DOI 10.1086/367989

[3] Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy:: a collaborative analysis of prospective studies [J].

Egger, M ;

May, M ;

Chêne, G ;

Phillips, AN ;

Ledergerber, B ;

Dabis, F ;

Costagliola, D ;

Monforte, AD ;

de Wolf, F ;

Reiss, P ;

Lundgren, JD ;

Justice, AC ;

Staszewski, S ;

Leport, C ;

Hogg, RS ;

Sabin, CA ;

Gill, MJ ;

Salzberger, B ;

Sterne, JAC .

LANCET, 2002, 360 (9327) :119-129

[4] Efficacy and safety of tenofovir DF vs stavuldine in combination therapy in antiretroviral-naive patients - A 3-year randomized trial [J].

Gallant, JE ;

Staszewski, S ;

Pozniak, AL ;

DeJesus, E ;

Suleiman, JMAH ;

Miller, MD ;

Coakley, DF ;

Lu, B ;

Toole, JJ ;

Cheng, AK .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (02) :191-201

[5] Changes in the rate of genotypic resistance to antiretroviral drugs in Spain [J].

Gallego, O ;

Ruiz, L ;

Vallejo, A ;

Ferrer, E ;

Rubio, A ;

Clotet, B ;

Leal, M ;

Soriano, V .

AIDS, 2001, 15 (14) :1894-1896

[6] An open-label assessment of TMC 125-a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRT1 resistance [J].

Gazzard, BG ;

Pozniak, AL ;

Rosenbaum, W ;

Yeni, GP ;

Staszewski, S ;

Arasteh, K ;

De Dier, K ;

Peeters, M ;

Woodfall, B ;

Stebbing, J ;

Vant' Klooster, GAE .

AIDS, 2003, 17 (18) :F49-F54

[7] Protease and reverse transcriptase mutation patterns in HIV type 1 isolates from heavily treated persons: Comparison of isolates from Northern California with isolates from other regions [J].

Gonzales, MJ ;

Belitskaya, I ;

Dupnik, KM ;

Rhee, SY ;

Shafer, RW .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 2003, 19 (10) :909-915

[8]

Health Protection Agency Scottish Centre for Infection and Environmental Health National Public Health Service for Wales Communicable Disease Surveillance Centre Northern Ireland Unlinked Anonymous Surveys Steering Group, 2003, REN FOC HIV OTH SEX

[9]

Johnson Victoria A, 2003, Top HIV Med, V11, P215

[10] Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine [J].

Kempf, DJ ;

King, MS ;

Bernstein, B ;

Cernohous, P ;

Bauer, E ;

Moseley, J ;

Gu, K ;

Hsu, A ;

Brun, S ;

Sun, E .

JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (01) :51-60

← 1 2 3 →